By analyzing multiple clinical cohorts, we evaluated the impact of MAP2K3 expression levels on tumor immunotherapy and found a significant prognostic advantage in the high MAP2K3 expression group after anti-PD-1 immunotherapy, which is consistent with our predicted results. This evidence concerns the gene PDCD1 and neoplasm.